Skip to main content

Table 1 Summary of phase III and retrospective study of CRT for elderly patients with esophageal cancer

From: Chemoradiation in elderly esophageal cancer patients: rationale and design of a phase I/II multicenter study (OSAGE)

Authors S n Age, mean, (range) Treatment Acute toxicities Late toxicities Survival
Song et al. R 82 76
(70–87)
Paclitaxel 135 mg/m2
J1-J29
Leucopenia G4 10% Esophageal stenosis 14,6% mean PFS 18,2 m
    CDDP 30 mg/m2
J1 J3 - J29 J31
Esophagitis G4 2% radiation pneumonia 7% 2 years PFS I-II 64%
    RTE 60 Gy Thrombopenia
G4 1%
2 years PFS III IV 21%
Su et al. R 96 73
(65–82)
5FU   radiation pneumonia 15% 1 year PFS 70,9 m
    CDDP    3 years PFS 52 m
    RTE 56–66 Gy Extensive or
conventional
 
Zhong et al. RA 79   RTE 56–59.4 Gy    mean PFS 19,7 m
    Docetaxel 25 mg/m2 and
CDDP 25 mg/m2 weekly
1 year 78,5 / 61,2
    post RTCT Docetaxel
60 mg/m2 and
CDDP 75 mg/m2
  
Wang Jing et al. R 100 76
(70–88)
CRT 50.4–66 CDDP-5FU-Docetaxel 4 courses Leucopenia 21% radiation pneumonia 13% mean PFS CRT 15 m
     Esophagitis 12% 1 year PFS CRT 58%
     Pneumonia 10%  
Li et al. R 32 74
(70–90)
RT 50–60 Gy Esophagitis G3–4: 25% mean PFS 23 m
    CT: Docetaxel weekly,
CDDP-5FU,
carboplatine-paclitaxel
    paclitaxel only, doxifluridine   
Zhonghua et al. R 89   RT 60 Gy: extensive or conventional Leucopenia G3 33% overall 3 year survival 32,8%
    CT paclitaxel 125 mg/m2
CDDP 20 (or oxaliplatine)
Uno et al. R 17 79
(75–85)
RT 50–60 Gy Leucopenia G3 2% median survival 9 months
    CT CDDP 5FU    OS 1 year 39%
Semrau et al. R 15 74.1 (70–85) RT 63 Gy   radiation pneumonia 4 pts OS 13,9 m
    CDDP 20 mg/m2 and 5FU Esophageal stenosis 9 pts mean PFS 9,5 m
Anderson et al. R 25 77
(66–88)
RT 50.4 Gy Leucopenia G4 16% mean OS 35 months
    CT 5FU Mitomycine   1 year OS 80%
Tougeron et al. R 109 74.4 (70–88) RTE 50–55 Gy Any G3 22% median OS 15,2 +/− 3 m
    5FU CDDP one toxic death from sepsis 2 year survival rates 35,5%
Tougeron et al. R 151 mean 75 +/−4.1 CRT 50–55 Gy,
CDDP 5FU
Any G3 24.3% (mainly vomiting) median OS 17,5 months
     and neutropenia 2-year survival 36,6%
Xu et al. R 20 76
(70–88)
CRT 5FU CDDP acute pneumonia G3–4: 5% OS 17 months
       CRT mean PFS 14 months
Mak et al. R 28 79.5 (75–89) CRT 50.4 Gy
5FU CDDP
any G4 38% Esophageal G3 17% median survival 12.4 months
     any G3 73.5% no late pulmonary
     acute neutropenia G4: 23.5%
     one death from sepsis  
Tumori et al. R 57 69 CRT    median survival 11,2 months
Servagi et al. RA 30 85
(79–92)
CRT 50Gy CDDP only or
Oxalipatin only
Dysphagia G4 13.3% radiation pneumonia 10% PFS at 1 year 40%
       Three year OS 22%
  1. Abbreviations: S study design, R retrospective study, RA Randomized study, G grade, PFS progression-free-survival, CRT chemoradiation, n number of patients, CDDP cisplatine